AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05626348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study NCT05626348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection
Description: Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study NCT05626348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study NCT05626348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study NCT05108935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study NCT05250479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness education
Description: 44 primiparous pregnant women will receive mindfulness education
Study NCT06445920 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT06641947 — intervention group
Intervention type: PROCEDURE
Intervention: Whipple procedure
Description: Typically used for treating pancreatic cancer, particularly tumors located in the head of the pancreas.
Study NCT06641505 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guiding rehydration
Description: Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
Study NCT05108935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study NCT05108935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: Enrolled participants will be prescribed PrEP Mavyret and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
Study NCT05682963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Square Step Exercises Program
Description: Intervention description: patient will be treated for eight weeks, two days a week, one session a day, and total 16 session. Each session will be 45 minute.
Study NCT05682963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Frenkel's coordination exercises will be applied as a home program for 8 weeks, 2 days a week, with each exercise session 15-30 minutes excluding rest periods.
Study NCT05545436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )
Description: Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ) Drug: Camrelizumab 200mg Drug: oxaliplatin 130 mg/m2 Drug: Teggio 40 mg/m2 Drug: oxaliplatin 130 mg/m2 Drug: capecitabine 1000 mg/m2 Q3W for 3 cycles. Radical surgery was performed 3 weeks after the last neoadjuvant treatment.
Study NCT06641505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guiding rehydration
Description: Preoperative fluid rehydration was performed according to 421 fluid rehydration principles
Study NCT06160180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Submucosal application
Study NCT06643689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.
Study NCT06643689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.
Study NCT06259500 — intervention group
Intervention type: OTHER
Intervention: observational
Description: Profiling the function of iPSC derived Arcuate neurons and PBMC derived microglia
Study NCT05038176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MANUP
Description: Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
Study NCT05038176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MANUP
Description: Intervention will include diabetes education, diabetes support with a focus on coping techniques (based on John Henryism concepts), physical activity engagement and motivational text messages.
Study NCT06321484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Memory-like Natural Killer Cells
Description: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.
Study NCT06321484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
Study NCT05233254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal Hollowing exercise
Description: Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out. Gently and slowly draw in your lower abdomen below your navel without moving your upper stomach, back and pelvis. Breathe in and out.
Study NCT04631471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibudilast
Description: Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
Study NCT04631471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical decompressive surgery
Description: Surgical decompression of degenerate cervical myelopathy
Study NCT04631471 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cervical decompressive surgery
Description: Surgical decompression of degenerate cervical myelopathy
Study NCT04631471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
Study NCT05167526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8731
Description: Oral
Study NCT05167526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASP8731 Matching Placebo
Description: Oral
Study NCT06178705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpful Parenting Program Intervention
Description: 8-10 sessions with 60 minutes duration once in a week will be conducted with the parents in group and one-on-one setting. Helpful parenting program would be based on social learning theory, behavior modification and couple counseling. The program will be used as an intervention strategy with parents to built insight about their child's emotional \& behavioral issues. Different strategies to teach parenting skills will also be used as an intervention. Further more, this program will target parents' psychological distress and couples' problematic conflicts regarding parenting
Study NCT04503291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metal stent placement
Description: Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
Study NCT06337643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01
Description: Pneumococcal Vaccine Candidate
Study NCT06337643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVX01 Placebo
Description: Placebo
Study NCT05203133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Balance
Description: Energy balance phase to elicit weight-maintenance
Study NCT05203133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Deficit
Description: Energy deficit phase to elicit weight-loss
Study NCT05203133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Baseline Assessment
Description: Free-living assessment of energy status
Study NCT05416931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD440 Gel 14mg/g
Description: Topical application to painful area
Study NCT05416931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Topical application to painful area
Study NCT05182502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel
Description: Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
Study NCT06447753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct pulp capping
Description: after caries excavation, the pulp will be inspected visually. If bleeding present, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Cases in which bleeding will not stop within 6 minutes will be excluded from the study and further managed by RCT. The exposed pulp will be capped with MTA which will be freshly mixed according to manufacturer's instructions and placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier following which the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. Then tooth will be restored using composite resin following etch and rinse technique.
Study NCT06447753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Pulpotomy
Description: exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant 28to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 6 minutes. After hemostasis, ProRoot MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier. After placement, the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. The tooth then will be restored using composite resin following etch and rinse technique.
Study NCT05765032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921；
Description: Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion
Study NCT06402474 — intervention group
Intervention type: PROCEDURE
Intervention: sunbed position
Description: 30° reverse trendelenburg legs together 30° hip flexion (sunbed position)
Study NCT05698407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.
Study NCT05698407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
Study NCT05369039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilust
Description: A selective phosphodiesterase 4 Inhibitor
Study NCT05369039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Systemic corticosteroid
Study NCT06016582 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Use of virtual reality hypnosis headset during frozen embryo transfer
Description: The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~* The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~* The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~* The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study.
Study NCT06322251 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of instrument to identify exposure to violence in close relationships
Description: Use of instrument to identify exposure to violence in close relationships
Study NCT06026267 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20% High Dose Albumin
Description: A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy.~Duration of albumin over 24 hours.
Study NCT00012727 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Matching Symptom Severity to Service Intensity
Study NCT05782101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Integrated proteomic HPLC-ESI-MS analysis of salivary peptides
Description: A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
Study NCT06026267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT06026267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT06026267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% Reduced Dose Albumin
Description: B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.~Duration of albumin over 24 hours.
Study NCT06113354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (MRace Implant and Delivery System)
Description: The MRace Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture~Other Names:~TMVr
Study NCT05217446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: capsule
Study NCT05217446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: IV
Study NCT04690283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mimetic granules of Yiqi-Wenjing prescriptions
Description: The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.
Study NCT04690283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huangqi-Guizhi-Wuwu granules
Description: The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.
Study NCT04690283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danggui-Sini granules
Description: The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
Study NCT06165419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT to the spine
Description: Stereotactic body radiation therapy (SBRT) administered to spine metastases
Study NCT05503992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention package
Description: The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
Study NCT00096850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
Study NCT00096850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
Study NCT05217446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV
Study NCT05217446 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV
Study NCT04702139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder arthroplastis
Description: - Group (Treatment): Placement of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
Study NCT00096850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
Study NCT06431776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.
Study NCT04702139 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: shoulder arthroplastis
Description: - Group (Control): Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
Study NCT05897138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
Description: Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle
Study NCT04922125 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pulse flour
Description: Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
Study NCT04922125 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pre-processed pulse flour
Description: Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
Study NCT04503291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal stent placement
Description: Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
Study NCT05751616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laminate veneers with speed sintering
Description: Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.
Study NCT05751616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laminate veneers with conventional sintering
Description: Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
Study NCT04812080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXPLORER PET/CT
Description: FDG PET Scans on the total body EXPLORER PET/CT scanner